Day: August 4, 2025

RADIANT study with vormatrigine in focal onset seizure (FOS) patients over eight weeks demonstrated 56.3% median reduction in seizure frequency from baseline, with 22% at 100% seizure reduction in last 28 days Initiated two registrational studies for Developmental and Epileptic Encephalopathies (DEEs) programs: EMERALD for broad DEEs with relutrigine and EMBRAVE3 for SCN2A Gain-of-Function (GoF) with elsunersen Relutrigine granted U.S. FDA Breakthrough Therapy Designation for the treatment of seizures associated with SCN2A and SCN8A DEEs, enabling expedited development Cash and investments of approximately $447 million as of June 30, 2025 maintains runway into 2028 Praxis to host a conference call today, August 4, at 8:30am to discuss Phase 2 RADIANT study results and provide a corporate update BOSTON, Aug. 04, 2025 (GLOBE NEWSWIRE)...

Returned over 100% of free cash flow year-to-date through share repurchases SCOTTSDALE, Ariz., Aug. 04, 2025 (GLOBE NEWSWIRE) — onsemi (the “Company”) (Nasdaq: ON) today announced its second quarter 2025 results with the following highlights:Revenue of $1,468.7 million GAAP gross margin and non-GAAP gross margin of 37.6% GAAP operating margin and non-GAAP operating margin of 13.2% and 17.3%, respectively GAAP diluted earnings per share and non-GAAP diluted earnings per share of $0.41 and $0.53, respectively Cash from operations of $184.3 million and free cash flow of $106.1 million“Our ongoing transformation is resulting in a more predictable business model, reflecting the strength of our strategy and our commitment to long-term value creation. We are beginning to see signs of stabilization across our end markets, and we remain...

Mural continues to explore strategic alternatives Estimates cash and cash equivalents of approximately $43 to $48 million at December 31, 2025, if it has not consummated a transaction or other strategic alternative by year end WALTHAM, Mass. and DUBLIN, Aug. 04, 2025 (GLOBE NEWSWIRE) — Mural Oncology plc (Nasdaq: MURA), today announced its financial results for the second quarter of 2025 and provided a business update. On April 15, 2025, Mural announced that it was discontinuing all clinical development of its lead product candidate, nemvaleukin alfa, and was commencing the exploration of strategic alternatives focused on maximizing shareholder value. The Company is continuing to explore strategic alternatives. Following its announcement on April 15, 2025, Mural has taken steps to conserve its remaining cash, including the implementation...

Key HighlightsPost financial year end, the Manager entered into an agreement to divest Jem office for S$462.0 million, in line with valuation. The transaction will strengthen Lendlease REIT’s capital structure, positioning it for future growth. Distribution per unit (“DPU”) for 2H FY2025 grew 1.8% year-on-year (“YoY”) to 1.80 cents. A more favourable interest rate outlook is expected to contribute positively towards distribution performance. Cost of debt for the financial year is at 3.46% per annum with interest coverage ratio (“ICR”)1,2 improved to 1.6 times. Portfolio valuation increased 2.2% YoY mainly supported by a positive outlook for our Singapore assets. The portfolio experienced positive rental growth, with a 10.2%3 reversion in retail and a 1.7%4 uplift in Milan’s commercial Building 1 and 2.SINGAPORE, Aug. 04, 2025 (GLOBE...

Multi-Protein Portfolio and Operational Focus Fuel Continued Top and Adjusted Bottom-Line Gains SPRINGDALE, Ark., Aug. 04, 2025 (GLOBE NEWSWIRE) — Tyson Foods, Inc. (NYSE: TSN), one of the world’s largest food companies and a recognized leader in protein with leading brands including Tyson, Jimmy Dean, Hillshire Farm, Ball Park, Wright, Aidells, ibp and State Fair, reported the following results:(in millions, except per share data) Third Quarter   Nine Months Ended    2025   2024   2025   2024  Sales $ 13,884   $ 13,353   $ 40,581   $ 39,744                           Operating Income $ 260   $ 341   $ 940   $ 884  Adjusted1 Operating Income (non-GAAP) $ 505   $ 491   $ 1,679   $ 1,308                           Net Income Per Share Attributable to Tyson $ 0.17   $ 0.54   $ 1.20   $ 1.25  Adjusted1 Net...